Marc Frahm
Stock Analyst at TD Cowen
(4.90)
# 261
Out of 4,468 analysts
414
Total ratings
56.7%
Success rate
26.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Marc Frahm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Maintained: Buy | $124 | $116.86 | +6.11% | 71 | Jun 22, 2026 | |
| AGIO Agios Pharmaceuticals | Maintained: Buy | n/a | $37.59 | - | 24 | Jun 16, 2026 | |
| DMRA Damora Therapeutics | Maintained: Buy | n/a | $29.98 | - | 2 | Jun 11, 2026 | |
| CGEM Cullinan Therapeutics | Maintained: Buy | n/a | $17.63 | - | 26 | Jun 10, 2026 | |
| NUVL Nuvalent | Downgraded: Hold | $124 | $123.73 | +0.22% | 17 | Jun 10, 2026 | |
| CRDF Cardiff Oncology | Maintained: Hold | n/a | $1.27 | - | 16 | Jun 4, 2026 | |
| RVMD Revolution Medicines | Maintained: Buy | n/a | $189.24 | - | 24 | Jun 1, 2026 | |
| ACRV Acrivon Therapeutics | Maintained: Buy | n/a | $1.72 | - | 12 | May 14, 2026 | |
| SANA Sana Biotechnology | Maintained: Buy | n/a | $4.01 | - | 14 | May 11, 2026 | |
| NKTR Nektar Therapeutics | Reiterated: Buy | n/a | $71.04 | - | 2 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 | $8.26 | -39.47% | 11 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $15 | $16.93 | -11.40% | 19 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $15.54 | - | 18 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $54.88 | - | 23 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $2.01 | - | 15 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $7.05 | - | 13 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $24.21 | - | 16 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $113.51 | - | 22 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $9.15 | - | 10 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $0.039 | n/a | 19 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.13 | n/a | 8 | Jan 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $94.34 | n/a | 10 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $150,000.00 | n/a | 6 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $3.22 | n/a | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $2.08 | n/a | 3 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $38.69 | n/a | 5 | Feb 26, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1,213.91 | n/a | 1 | Jan 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $297.65 | n/a | 6 | Dec 4, 2018 |
Incyte
Jun 22, 2026
Maintained: Buy
Price Target: $124
Current: $116.86
Upside: +6.11%
Agios Pharmaceuticals
Jun 16, 2026
Maintained: Buy
Price Target: n/a
Current: $37.59
Upside: -
Damora Therapeutics
Jun 11, 2026
Maintained: Buy
Price Target: n/a
Current: $29.98
Upside: -
Cullinan Therapeutics
Jun 10, 2026
Maintained: Buy
Price Target: n/a
Current: $17.63
Upside: -
Nuvalent
Jun 10, 2026
Downgraded: Hold
Price Target: $124
Current: $123.73
Upside: +0.22%
Cardiff Oncology
Jun 4, 2026
Maintained: Hold
Price Target: n/a
Current: $1.27
Upside: -
Revolution Medicines
Jun 1, 2026
Maintained: Buy
Price Target: n/a
Current: $189.24
Upside: -
Acrivon Therapeutics
May 14, 2026
Maintained: Buy
Price Target: n/a
Current: $1.72
Upside: -
Sana Biotechnology
May 11, 2026
Maintained: Buy
Price Target: n/a
Current: $4.01
Upside: -
Nektar Therapeutics
May 8, 2026
Reiterated: Buy
Price Target: n/a
Current: $71.04
Upside: -
May 8, 2026
Maintained: Hold
Price Target: $5
Current: $8.26
Upside: -39.47%
May 8, 2026
Rated: Hold
Price Target: $15
Current: $16.93
Upside: -11.40%
May 8, 2026
Maintained: Buy
Price Target: n/a
Current: $15.54
Upside: -
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $54.88
Upside: -
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $2.01
Upside: -
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $7.05
Upside: -
May 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $24.21
Upside: -
May 5, 2026
Maintained: Buy
Price Target: n/a
Current: $113.51
Upside: -
Nov 13, 2025
Maintained: Buy
Price Target: n/a
Current: $9.15
Upside: -
Nov 14, 2024
Maintained: Buy
Price Target: n/a
Current: $0.039
Upside: n/a
Jan 12, 2024
Rated: Hold
Price Target: n/a
Current: $4.13
Upside: n/a
Jan 26, 2023
Downgraded: Hold
Price Target: n/a
Current: $94.34
Upside: n/a
Mar 22, 2021
Downgraded: Hold
Price Target: n/a
Current: $150,000.00
Upside: n/a
Mar 2, 2021
Initiated Coverage: Buy
Price Target: n/a
Current: $3.22
Upside: n/a
Aug 5, 2020
Maintained: Buy
Price Target: n/a
Current: $2.08
Upside: n/a
Feb 26, 2019
Initiated Coverage: Hold
Price Target: n/a
Current: $38.69
Upside: n/a
Jan 7, 2019
Downgraded: Hold
Price Target: n/a
Current: $1,213.91
Upside: n/a
Dec 4, 2018
Maintained: Buy
Price Target: n/a
Current: $297.65
Upside: n/a